iPreFlight Genesis™ Pro Significantly Extends APG’s Industry-leading Performance Solutions by Adding Proven and Fully Integrated International Flight Planning and Management Workflow for Dispatchers and Flight Crews
11.10.2021 23:29:00 EEST | Business Wire | Press release
NBAA-BACE – Aircraft Performance Group (APG) announces iPreFlight Genesis™ Pro, a new solution that seamlessly coordinates between aircraft dispatchers and flight crews, enabling optimized global flight planning with integrated enroute, take-off, and landing performance. iPreFlight Genesis Pro is the culmination of APG’s proven track record of 20+ years of providing trusted runway performance for over 350 aircraft profiles and over 9,000 monitored airports combined with RocketRoute’s global routing and filing capabilities and Seattle Avionics’ global ChartData. APG, RocketRoute, and Seattle Avionics all recently joined forces under the AFV Partners LLC umbrella.
iPreFlight Genesis Pro provides optimized and fully integrated tools for both dispatchers and flight crews. Dispatchers have access to a comprehensive and flexible web-based application for global routing, runway performance, weight and balance, and flight plan calculation and filing. Flight crews can use the iPad application to review and modify trip plans at any point during the mission, verify runway performance calculations, and check weight and balance parameters. Routes and flight plans are fully synchronized between the web and iPad applications enabling seamless bi-directional collaboration between pilots and dispatchers, eliminating inefficient phone calls, significantly decreasing operational change reaction times, and improving communication accuracy.
“Flight preparation boils down to one important question: What is the most safe, compliant, efficient, and timely manner to get to my destination based on optimized routing considering my aircraft's performance capabilities?” said Shawn Mechelke, president of the Aviation Group at AFV Partners. “APG’s runway performance system is the industry leader in business aviation. Now, with global route optimization and flight plan filing from RocketRoute and global charts from Seattle Avionics, iPreFlight Genesis Pro brings together the many data, calculations, and performance considerations into a seamless interface that is powerful, easy to use, and integrated in both mobile and web applications – no matter where in the world a mission takes you.”
“iPreFlight Genesis Pro uniquely combines the assets and IP of all three companies within our Aviation Group to optimize the flight route based on multiple parameters such as type of aircraft, load factor, weather conditions, and many more data points to deliver a high return on investment solution with a meaningful sustainability impact due to an optimized fuel burn profile for our customers,” said Tony Aquila, founder, chairman, and CEO of AFV Partners. “This solution is the first of many that will leverage the people, technology, and data across APG, RocketRoute, and Seattle Avionics to create new products that will have a lasting positive impact on aviation and the environment.”
KEY BENEFITS
- Realtime responsiveness delivers a superior experience to clients
- Simplifies dispatcher and crew workflow
- Lowers training costs
- Reduces unplanned downtime
- Lowers operating costs and total cost of ownership
KEY FEATURES
- Bi-directional synchronization between dispatchers and flight crews
- Integrated runway performance with flight planning
- Global routing and filing
- Weight and Balance
- Global charts for in-flight and pre-flight use
- Supports web platforms and mobile devices
- Application Programming Interfaces (APIs) allow connection to customer applications
About Aircraft Performance Group
Aircraft Performance Group (APG) is a leading global provider of proprietary flight operations software solutions into the aftermarket of the aerospace industry. APG operates a SaaS business model focused on the corporate and business aviation segment of the aerospace industry. www.flyapg.com
About RocketRoute
RocketRoute is a leading software platform simplifying route planning and flight plan submissions to air traffic controllers. RocketRoute solutions span private, business and commercial aviation, and are the backbone to many air rescue operations in Europe. www.rocketroute.com
About Seattle Avionics
Seattle Avionics creates compelling pre-flight and in-flight user experiences with its cloud-based solutions providing direct user access to flight planning, weather, fuel prices and group document management for the general aviation market. Their ChartData brand of global FAA-certified and georeferenced charts and data is proven and used in leading in-panel avionics systems around the world. www.seattleavionics.com
About AFV Partners
Founded by serial technology entrepreneur and investor Tony Aquila and anchored by some of the world’s largest and most experienced investors, AFV Partners is a long-term sustainable capital vehicle that invests globally in mission critical software, data and disruptive marketplaces that contribute to a net positive impact on the environment. AFV Partners is headquartered in Argyle, TX with offices in Jackson Hole, WY and Zurich, Switzerland. www.afvpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005683/en/
Contact information
John Rutter
johnr@seattleavionics.com
+1 206 779 2067
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom